507 related articles for article (PubMed ID: 17502572)
1. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans.
Lavi S; McConnell JP; Rihal CS; Prasad A; Mathew V; Lerman LO; Lerman A
Circulation; 2007 May; 115(21):2715-21. PubMed ID: 17502572
[TBL] [Abstract][Full Text] [Related]
2. Association of Lp-PLA2 with digital reactive hyperemia, coronary flow reserve, carotid atherosclerosis and arterial stiffness in coronary artery disease.
Ikonomidis I; Kadoglou NN; Tritakis V; Paraskevaidis I; Dimas K; Trivilou P; Papadakis I; Tzortzis S; Triantafyllidi H; Parissis J; Anastasiou-Nana M; Lekakis J
Atherosclerosis; 2014 May; 234(1):34-41. PubMed ID: 24594367
[TBL] [Abstract][Full Text] [Related]
3. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
Sabatine MS; Morrow DA; O'Donoghue M; Jablonksi KA; Rice MM; Solomon S; Rosenberg Y; Domanski MJ; Hsia J;
Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2463-9. PubMed ID: 17766330
[TBL] [Abstract][Full Text] [Related]
4. Higher lipoprotein-associated phospholipase A2 levels are associated with coronary atherosclerosis documented by coronary angiography.
Dohi T; Miyauchi K; Ohkawa R; Nakamura K; Thuboi S; Ogita M; Miyazaki T; Nishino A; Yokoyama K; Kurata T; Yatomi Y; Daida H
Ann Clin Biochem; 2012 Nov; 49(Pt 6):527-33. PubMed ID: 22933444
[TBL] [Abstract][Full Text] [Related]
5. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z
Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606
[TBL] [Abstract][Full Text] [Related]
6. Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome.
Rosenson RS
Am Heart J; 2008 Mar; 155(3):499.e9-16. PubMed ID: 18294485
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) in acute coronary syndrome: relationship with low-density lipoprotein cholesterol.
Jabor B; Choi H; Ruel I; Hafiane A; Mourad W; Genest J
Can J Cardiol; 2013 Dec; 29(12):1679-86. PubMed ID: 24267807
[TBL] [Abstract][Full Text] [Related]
8. Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
Charniot JC; Khani-Bittar R; Albertini JP; Giral P; Cherfils C; Cosson C; Guillerm E; Leprince P; Gandjbakhch I; Bonnefont-Rousselot D
Int J Cardiol; 2013 Sep; 168(1):132-8. PubMed ID: 23103135
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans.
Yang EH; McConnell JP; Lennon RJ; Barsness GW; Pumper G; Hartman SJ; Rihal CS; Lerman LO; Lerman A
Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):106-11. PubMed ID: 16239595
[TBL] [Abstract][Full Text] [Related]
10. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.
Kiechl S; Willeit J; Mayr M; Viehweider B; Oberhollenzer M; Kronenberg F; Wiedermann CJ; Oberthaler S; Xu Q; Witztum JL; Tsimikas S
Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1788-95. PubMed ID: 17541022
[TBL] [Abstract][Full Text] [Related]
11. Smoking is associated with epicardial coronary endothelial dysfunction and elevated white blood cell count in patients with chest pain and early coronary artery disease.
Lavi S; Prasad A; Yang EH; Mathew V; Simari RD; Rihal CS; Lerman LO; Lerman A
Circulation; 2007 May; 115(20):2621-7. PubMed ID: 17485580
[TBL] [Abstract][Full Text] [Related]
12. Circulating lipoprotein-associated phospholipase A2 in high-grade carotid stenosis: a new biomarker for predicting unstable plaque.
Sarlon-Bartoli G; Boudes A; Buffat C; Bartoli MA; Piercecchi-Marti MD; Sarlon E; Arnaud L; Bennis Y; Thevenin B; Squarcioni C; Nicoli F; Dignat-George F; Sabatier F; Magnan PE;
Eur J Vasc Endovasc Surg; 2012 Feb; 43(2):154-9. PubMed ID: 22075154
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target.
Carlquist JF; Muhlestein JB; Anderson JL
Expert Rev Mol Diagn; 2007 Sep; 7(5):511-7. PubMed ID: 17892360
[TBL] [Abstract][Full Text] [Related]
14. Chronic inhibition of lipoprotein-associated phospholipase A
Prasad M; Lennon R; Barsness GW; Prasad A; Gulati R; Lerman LO; Lerman A
Int J Cardiol; 2018 Feb; 253():7-13. PubMed ID: 29306475
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein phospholipase A2 mass and activity are not associated with the diagnosis of acute brain ischemia.
Tai W; Garcia M; Mlynash M; Kemp S; Albers GW; Olivot JM
Cerebrovasc Dis; 2014; 38(5):324-7. PubMed ID: 25428761
[TBL] [Abstract][Full Text] [Related]
16. Utility of Lp-PLA2 in lipid-lowering therapy.
Racherla S; Arora R
Am J Ther; 2012 Mar; 19(2):115-20. PubMed ID: 20634673
[TBL] [Abstract][Full Text] [Related]
17. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
18. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity.
Kerekes G; Szekanecz Z; Dér H; Sándor Z; Lakos G; Muszbek L; Csipö I; Sipka S; Seres I; Paragh G; Kappelmayer J; Szomják E; Veres K; Szegedi G; Shoenfeld Y; Soltész P
J Rheumatol; 2008 Mar; 35(3):398-406. PubMed ID: 18203326
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein-associated phospholipase A2.
McConnell JP; Hoefner DM
Clin Lab Med; 2006 Sep; 26(3):679-97, vii. PubMed ID: 16938590
[TBL] [Abstract][Full Text] [Related]
20. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
Saougos VG; Tambaki AP; Kalogirou M; Kostapanos M; Gazi IF; Wolfert RL; Elisaf M; Tselepis AD
Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2236-43. PubMed ID: 17656665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]